Policy #	Policy Name	Type of Change	Brief Description of Policy Change	Reason for Changes
NEW	Itovebi (inavolisib)	Positive	1) Itovebi (inavolisib) may be used in combination with Ibrance (palbociclib) and Faslodex (fulvestrant) in adult members for the treatment of endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. 2) Added note that Evolent recommends that inavolisib is not administered to patients with Type 1 or Type 2 Diabetes Mellitus (DM) on anti-hyperglycemic therapy. These patients were excluded from the clinical trial and increased fasting glucose occurred in the majority of patients.	New FDA Drug/Indication
UM ONC_1194	Nexavar (soraferib)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1219	Jevtana (cabazitaxel)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1222	Erivedge (vismodegib)	No clinical change	1) Updated NCH verbiage to Evolent 2) Added new reference 3) Updated maximum dosage form quantities in exclusion criteria	Other
UM ONC_1223	Inlyta (axitinib)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1224	Kyprolis (carfilzomib)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1265	Zykadia (ceritinib)	No clinical change	1) Updated NCH verbiage to Evolent 2) Added new references 3) Updated maximum dosage form quantities in exclusion criteria	Other
UM ONC_1281	Empliciti (elotuzumab)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1335	Braftovi (encorafenib)	No clinical change	1) Updated NCH verbiage to Evolent 2) Added new reference	Other
UM ONC_1344	Poteligeo (mogamulizumab-kpkc)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1384	Targretin (bexarotene)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1391	Thalomid (thalidomide)	No clinical change	1) Updated NCH verbiage to Evolent 2) Updated maximum dosage form quantities in exclusion criteria	Other
UM ONC_1397	Mektovi (binimetinib)	No clinical change	Updated NCH verbiage to Evolent	Other

UM ONC_1419	Danyelza (naxitamab-gqgk)	No clinical change	1) Updated NCH verbiage to Evolent 2) Added new references	Other
UM ONC_1454	Besremi (ropeginterferon alfa-2b-nijft)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1466	Lytgobi (futibatinib)	No clinical change	1) Updated NCH verbiage to Evolent 2) Updated maximum dosage form quantities in exclusion criteria	Other
UM ONC_1467	Pedmark (sodium thiosulfate)	No clinical change	Updated NCH verbiage to Evolent	Other
UM ONC_1487	Aphexda (motixafortide)	No clinical change	Updated indication verbiage	Other
UM ONC_1488	Ojjaara (momelotinib)	No clinical change	1) Updated indication verbiage 2) Updated maximum dosage form quantities in exclusion criteria	Other
EMOD.0001	Medical Oncology Drug List Policy	Positive	No Changes	Other
UM ONC_1287	Tagrisso (osimertinib)	Positive	1) Added new indication 2) Updated maximum dosage form quantities in exclusion criteria 3) Updated references	New FDA Drug/Indication
UM ONC_1405	Retevmo (selpercatinib)	Positive	1) Policy already contains indication 2) Added new tablet strengths to exclusion criteria 3) Updated maximum dosage form quantities in exclusion criteria 4) Updated references	New FDA Drug/Indication
UM ONC_1274	Opdivo (nivolumab)	Positive	1) Updated NSCLC indication with: Opdivo (nivolumab) may be used as neoadjuvant therapy in combination with platinum doublet chemotherapy for up to 4 cycles in members with early stage IB-IIIA NSCLC with tumor size greater than or equal to 4 cm that is negative for EGFR and ALK mutation, regardless of the tumor PD-L1 status, followed by single-agent Opdivo (nivolumab) after surgery as adjuvant treatment for a maximum of 13 cycles 2) Updated references	New FDA Drug/Indication
UM ONC_1028	Bevacizumab Products	Positive	1) Updated HCC indication section to include adjuvant treatment in combination with atezolizumab in adult members with high risk of recurrence 2) Added criteria for high risk of recurrence 3) Updated references	Compendia Listing

UM ONC_1206	Xalkori (crizotinib)	Positive	1) Updated dosage forms, and added oral pellet strengths to exclusion criteria 2) Updated maximum dosage form quantities in exclusion criteria 3) Updated references	Other
UM ONC_1221	Bosulif (bosutinib)	Positive	1) Updated dosage forms, and added new capsule strengths to exclusion criteria 2) Updated maximum dosage form quantities in exclusion criteria 3) Updated references	Other
UM ONC_1299	Tecentriq and Tecentriq Hybreza (atezolizumab IV/SC)	Positive	1) Updated HCC indication section to include adjuvant treatment in combination with bevacizumab/bevacizumab biosimilar in adult members with high risk of recurrence 2) Added criteria for high risk of recurrence 3) Updated references	Compendia Listing
UM ONC_1328	Verzenio (abemaciclib)	Positive	1) Updated maximum dosage form quantities in exclusion criteria 2) Updated references	Other
UM ONC_1349	Talzenna (talazoparib)	Positive	1) Updated dosage forms, and added new capsule strengths to exclusion criteria 2) Updated maximum dosage form quantities in exclusion criteria 3) Updated references	Other
UM ONC_1367	Rozlytrek (entrectinib)	Positive	1) Updated dosage forms, and added oral pellet strengths to exclusion criteria 2) Updated maximum dosage form quantities in exclusion criteria 3) Updated references	Other
UM ONC_1376	Oxbryta (voxelotor)	Positive	1) Added the following note under indication section: On September 25, 2024, Pfizer Inc., the manufacturer of Oxbryta (voxelotor), announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded access programs for Oxbryta because recent data indicate the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population. 2) Will archive policy at 1-year mark of drug withdrawal (September 2025) 3) Updated references	Archive Guideline

UM ONC_1442	Truseltiq (infigratinib)	Positive	1) Policy already states: On October 2022, the manufacturer withdrew its New Drug Application for the FDA and decided to permanently discontinue US distribution of the drug. 2) Added the additional following note: On May 16, 2024, the FDA announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. The accelerated approval of infigratinib required the sponsor to conduct postmarketing trials to verify the clinical benefit of the drug. The sponsor voluntarily requested withdrawal of infigratinib. 3) Will archive policy at 1-year mark of drug withdrawal (May 2025) 4) Updated references 5) Updated NCH verbiage to Evolent	Archive Guideline